GE and Philips Own the Bedside. These Ten Companies Are Building Everything Else.
The NICU's core infrastructure is locked up. These ten startups are building the five layers the incumbents left open — wireless monitoring, neonatal nutrition, brain surveillance, family workflow, and hospital-to-home transition.
Pediatric Health Dispatch — Deep Dispatch | May 29, 2026
The Bottom Line
- The NICU's core bedside infrastructure (monitors, incubators, ventilators) has been dominated by GE HealthCare, Philips, Masimo, and Dräger for decades, and that is not changing. What is changing is the five layers those incumbents never built: wireless monitoring, neonatal nutrition, brain surveillance, family workflow, and hospital-to-home transition. Startups now own those wedges, and the clinical evidence is stacking up to prove they matter.
- FDA clearances have arrived in quick succession across the NICU startup stack: Sibel Health's seventh clearance in April 2026, PyrAmes's Boppli cleared in 2023 and now moving toward commercialization through a Sentec partnership, CergenX Wave earning Breakthrough Device Designation, and Prapela's De Novo authorization for neonatal opioid withdrawal in April 2025. The NICU is not waiting for the science; it is waiting for the distribution.
- The April 2026 consolidation wave (Natus's acquisitions of Keriton and TheraB, AngelEye's acquisition of SupportSpot) means the exit window for point solutions is narrowing. Builders who understand which layer of the stack they occupy, and what that position is worth to a platform assembler, are better positioned than those building in isolation without a theory of where they fit.
The Stack the Incumbents Left Open
The NICU is one of medicine's most technology-dense environments. A level IV neonatal intensive care unit at a major children's hospital will run GE HealthCare or Philips bedside monitors, Masimo pulse oximeters, Dräger incubators and ventilators, and a Natus hearing screener at minimum. The combined installed base of those four companies in U.S. NICUs represents decades of capital investment, clinical workflow integration, and regulatory clearance. No startup is going to displace the Philips IntelliVue at the bedside.
But something important follows from that: the incumbents built their platforms around the acute, hardware-intensive core of NICU care, and largely left everything else. Family communication. Nutrition protocol compliance. Continuous noninvasive blood pressure monitoring for infants who can't tolerate arterial lines. Brain surveillance for babies at risk of neonatal seizures. The hospital-to-home handoff. These are not minor gaps. They are, in many cases, the difference between a family that understands what is happening to their baby and one that doesn't, between an infant who receives optimized nutrition from the first days of life and one who doesn't, between a discharge that sticks and one that leads to a readmission.
The NICU and neonatal care market covers roughly 380,000 admissions annually in the United States. A 2017–2022 analysis of 234,571 NICU admissions at U.S. children's hospitals found that median standardized hospital costs grew about 20% over that period, with measurable increases in both complexity and volume among the most preterm patients. Acuity is rising. Costs are rising. And the startup layer of the stack, the companies building into the gaps the incumbents left open, has spent the last three years collecting FDA clearances, signing health system contracts, and building the clinical evidence that makes the next-generation NICU possible.
This is not the story of who is buying those companies. PHD covered that angle in April, when Natus Sensory acquired Keriton and TheraB Medical in 14 days and AngelEye acquired SupportSpot a month later. This is the story of who is building, what they are building, and why those specific wedges matter now.
Five Wedges, Ten Companies
The most useful way to read the current NICU startup landscape is not as a flat list of interesting companies. It is as five product categories, each with a distinct buyer problem and a distinct relationship to the incumbents that don't address it.
The cables running off a NICU infant are not merely inconvenient. They restrict the kangaroo care (skin-to-skin holding) that clinical evidence consistently links to better respiratory, neurodevelopmental, and attachment outcomes.
Sibel Health
Wireless Monitoring
Sibel Health has spent six years and $89M in funding building toward the specific goal of eliminating that cable burden without sacrificing clinical-grade data. Its ANNE platform, now carrying seven FDA 510(k) clearances, uses soft wearable sensors to capture multiparameter vital signs, and its April 2026 clearance for ANNE Maternal extended the platform from neonates to the maternal-fetal monitoring context. Drager is a Sibel investor. That is not a coincidence: it is the clearest possible signal that an incumbent sees soft wearable monitoring as the direction of the category and has decided a strategic stake is worth more than trying to build it internally.
PyrAmes
Wireless Monitoring
PyrAmes approaches wireless monitoring from a more targeted angle. Its Boppli device delivers continuous, noninvasive blood pressure monitoring for critically ill infants, and its 2023 FDA 510(k) clearance was followed by a commercialization partnership with Sentec that gives PyrAmes a route to market without having to build a hospital sales force from scratch. The problem Boppli addresses is specific: current standard-of-care for continuous infant blood pressure monitoring requires an arterial line, which is invasive, painful, and carries infection risk. A wireless noninvasive alternative that produces continuous readings rather than intermittent cuff measurements is a meaningful clinical upgrade. PyrAmes has also received support from the March of Dimes Innovation Fund and a CTIP pediatric-device award, which together reflect genuine external validation of the problem's clinical significance.
Feeding is one of the most consequential and protocol-driven aspects of NICU care. An extremely premature infant's gastrointestinal system is immature; getting the caloric density, volume, timing, and type of milk right is not a simple task, and the consequences of getting it wrong, including necrotizing enterocolitis, can be catastrophic.
Astarte Medical
Neonatal Nutrition
Astarte Medical builds NICUtrition, an EMR-integrated decision-support and workflow platform designed to standardize feeding protocols, optimize nutrition, and reduce variability in neonatal care. Feeding standardization is one of those domains where the clinical evidence for reducing variation is strong but uptake is slow because it requires behavior change across nursing and attending teams. NICUtrition turns a complex, protocol-laden clinical domain into software. Its Series A-1 in 2021 was led by Viking Global Investors, which is not a typical early neonatal health tech investor: it is a signal that someone with real capital believed in the commercial thesis.
MMIB
Neonatal Nutrition
MMIB, which stands for Mother's Milk Is Best, is earlier-stage and more device-focused. It is building a point-of-care human milk concentration system that removes water from mother's own milk to create higher-nutrient, lower-volume feedings for preterm infants. The clinical case is grounded in a real problem: very-low-birth-weight infants need calorie-dense nutrition but cannot tolerate large feeding volumes, and standard fortification protocols often rely on cow-based additives that some clinicians believe carry NEC risk. MMIB's device would let NICU teams deliver concentrated mother's own milk instead. The company is small, grant-funded, and still in development — it belongs on this list because the problem it is attacking, the nutrition-delivery workflow for the most vulnerable NICU patients, is one that the major feeding companies (Medela, Prolacta) do not address in the same way.
Neonatal brain injury is one of the NICU's most consequential clinical events. Identifying which infants are at risk, and doing so quickly enough to intervene, has historically required a neurophysiologist to interpret a continuous aEEG recording — specialized, time-consuming, and not available at every institution. Two companies are trying to change this without requiring a specialist in the room.
CergenX
Neuromonitoring & Neonatal AI
CergenX is building CergenX Wave, an AI-guided newborn brain assessment tool designed to identify infants at highest risk of brain injury in minutes. Its FDA Breakthrough Device Designation, received in January 2025, reflects the agency's view that the device could provide more effective diagnosis or treatment of a life-threatening condition. CergenX's framing is important: this is decision support for frontline NICU clinicians, not a neurology referral tool. Making neonatal brain surveillance accessible to the staff who are already at the bedside is a different product bet than building a better EEG for tertiary centers that already have neurophysiology resources.
NeuroBell
Neuromonitoring & Neonatal AI
NeuroBell approaches the same problem from a portability angle. Its wireless EEG monitor is designed for bedside use by ordinary NICU staff, with automated seizure detection algorithms that flag clinical events without requiring expert interpretation. The company is a spinout from University College Cork and is at seed stage. NeuroBell is early, but the product philosophy — making neonatal seizure detection something that happens continuously in the NICU rather than episodically when a specialist is called — reflects a genuine clinical insight about how NICU teams actually operate.
Family-centered care has been a stated NICU philosophy for decades. The infrastructure to actually support it, at the level of product rather than principle, is still being built.
AngelEye Health
Family Workflow & Bedside Communication
AngelEye Health is the most established company in this category: its platform gives parents camera access to their infants, gives care teams a communication and engagement layer, and now, through its March 2026 acquisition of SupportSpot, adds psychosocial education and procedural preparation content for families across pediatric inpatient settings. Six of the top 10 U.S. News NICUs use AngelEye technology. Its Nationwide Children's Hospital strategic investment is not a passive endorsement; it is a children's health system buying into the platform thesis rather than building its own version.
Nicolette
Family Workflow & Bedside Communication
Nicolette is smaller, earlier, and more narrowly focused on a specific gap AngelEye does not address: translating raw NICU electronic medical record data into something a family can understand at the bedside. NicoBoard converts vital signs, labs, and clinical notes into plain-language trends, visual summaries, educational content, and action prompts for parents. Its co-founder's experience parenting extremely premature twins shapes the product's clarity of purpose in a way that is evident in the design. HITRUST certification in 2025 positioned Nicolette for health-system buyers with strict security requirements. The company has served more than 2,000 NICU families since its first deployment at CHOC — a modest number, but in a market where most of the "family engagement" conversation is still about philosophy rather than software, it represents validated commercial traction at a children's hospital that had no obligation to adopt it.
The hospital-to-home handoff for NICU graduates is, as PHD detailed in the May 14 Deep Dive, one of the most expensive and preventable failures in pediatric care.
Locus Health
NICU-to-Home Transition
Locus Health is the most commercially legible infrastructure company on the discharge side of the NICU stack. Its remote patient monitoring platform supports 70+ care pathways across 25+ states and integrates with Owlet's BabySat FDA-cleared infant pulse oximeter for continuous oxygen saturation monitoring after discharge. The Vanderbilt NICU Bridge to Home program, which used Locus Health's platform on pre-loaded tablets with daily feeding and weight logs and weekly telehealth appointments, showed measurable improvement in discharge support for enrolled infants. Locus is not a single-product company; it is the platform layer that makes post-discharge monitoring possible regardless of which clinical program is running on top of it.
The Business Model Question Nobody Is Answering Yet
Here is the tension that sits underneath every company on this list: the clinical case is solid, the regulatory path is clearing, and the health system interest is real. The scaling economics are harder to explain.
With a few exceptions, the NICU startup stack is selling capital equipment or software into hospital budgets. That is a legitimate business model. Hospitals buy Sibel Health sensors for neonates rather than running cables across a fragile premature infant. They buy NICUtrition to reduce feeding variation. They buy AngelEye because family-centered care is now a regulatory and accreditation expectation, not just a philosophy.
But hospital software and device sales into children's hospitals are slow, relationship-intensive, and often budget-constrained in ways that standard enterprise software sales are not. Children's hospitals operate on thin margins. NICU nursing shortages mean that any product requiring meaningful staff behavior change faces an adoption hurdle that is unrelated to its clinical value. And none of the companies in the family workflow or discharge transition categories have yet built a reimbursement-driven revenue model: Nicolette, Locus Health, and AngelEye all earn primarily through health system contracts rather than payer relationships.
The exceptions are instructive. ProgenyHealth, which is not on this list as a NICU product company but functions as important context, is payer-facing: it provides NICU utilization management and case management for health plans, including Humana Healthy Horizons in Kentucky, and its growth investment from Cressey & Company in 2025 reflects confidence in that payer-infrastructure model. A NICU care management layer that sits on the payer side, rather than the hospital side, can grow without depending on hospital budget cycles and without requiring the clinical behavior change that makes hospital software adoption slow.
The broader question for investors and founders is which of the five wedges eventually develops a reimbursable clinical-service layer, and which ones remain device or software sales into hospitals. Sibel and PyrAmes are classic medtech: device clearances, hospital capital budgets, procedure-driven economics. Astarte and Nicolette are clinical software: SaaS or licensing into health system accounts. AngelEye is the furthest along toward a platform model where multiple revenue streams (cameras, communication, clinical tools, family engagement content) compound off a single installed base. Locus Health is the most positioned to become a reimbursed RPM infrastructure player as payer coverage for post-discharge infant monitoring expands.
Vitara Biomedical
Beyond the Five Wedges
Vitara Biomedical is in a different category entirely. Vitara is developing EXTEND, a fluid-filled extra-uterine support system for infants born at the edge of viability — as early as 22 weeks — designed to protect against the lung injury and physiologic stress of immediate air exposure. The company has raised $125M, named a new CEO in late 2024 to push toward first-in-human trials, and is backed by Sands Capital, GV, and Khosla Ventures. EXTEND is not a NICU workflow product; it is an attempt to redefine what it means for an extremely premature infant to survive. It does not fit cleanly into any of the five wedges described above. It belongs on any honest list of companies that might fundamentally change neonatal care, with the understanding that "might" is doing serious work in that sentence. No other company in the neonatal startup landscape is attempting anything at the same level of ambition, and no other company is as far from revenue.
The most important strategic signal across all ten companies, taken together, is this: the gap between "interesting clinical startup" and "commercially scaled NICU infrastructure company" is still wide, and the consolidation wave of early 2026 means that the path to scale for most of these businesses likely runs through a platform acquirer rather than an independent growth trajectory. Natus, AngelEye, and any sufficiently capitalized children's health system that decides to build rather than buy are the most plausible consolidators. Sibel Health's Drager investment and PyrAmes's Sentec partnership are two examples of incumbents choosing the minority stake or distribution deal as a lower-cost alternative to acquisition. The exits will not all look like the Keriton deal. They will increasingly look like channel partnerships that blur the line between independence and absorption.
The NICU innovators who will matter in five years are not necessarily the ones with the most ambitious technology today. They are the ones who understand what layer of the stack they occupy, what a platform buyer would pay for that layer, and how to build clinical adoption fast enough to make themselves worth acquiring before the strategic window closes.
What We're Watching
- Whether Sibel Health or PyrAmes announces a meaningful health system expansion or new institutional partnership in the next two quarters. Both companies have FDA clearances and commercialization infrastructure in place. The next signal is clinical adoption at scale: not pilot deployments at academic centers that already have a research relationship, but operational rollouts at health systems that adopted the products on their clinical and budget merits.
- Whether any NICU-adjacent company develops an explicit payer-contracting model for monitoring or care management services. The reimbursement infrastructure for post-discharge infant monitoring is not fully built. As CMS and Medicaid managed care plans respond to the OBBBA's discharge-pressure dynamics, the companies that can document outcomes and bill for remote monitoring of NICU graduates will be structurally better positioned than those selling only into hospital capital budgets.
- When Vitara Biomedical announces a first-in-human study date. The company's last public statement on clinical timeline was at its November 2024 Series B close. A first-in-human trial for the EXTEND system would be a landmark moment for extreme prematurity research and would signal whether the $125M in capital behind it is translating into a regulatory path. Track this one for the next 18 months.
Pediatric Health Dispatch publishes every Tuesday (curated roundup) and Thursday (deep-dive analysis). Subscribe at pedshealthdispatch.com.